Topic

Articles

The renaming comes after the sale of Bosch Packaging Technology to CVC Capital Partners was completed on Jan. 2, 2020. 

Bosch Packaging Technology Becomes Syntegon Technology After Successful Transaction

Through the agreement, Eli will expand its immunology pipeline with lebrikizumab, Dermira’s novel, investigational, monoclonal antibody designed to bind interleukin-13 with high affinity.

Eli Lilly to Acquire Dermira for $1.1 Billion

The new business unit, as well as a new leadership team formed by AbbVie, will be effective upon closing of the acquisition in the first quarter of 2020.

AbbVie Spins Out New Business Unit Following Completion of $63-Billion Allergan Acquisition

Privately owned global pharmaceutical company, Galen, has announced the completion of its acquisition of a boutique healthcare company, POA Pharma.


Galen Completes Acquisition of POA Pharma

Through the acquisition, Johnson & Johnson will gain access to Taris’ lead clinical-stage product, TAR-200. 

Johnson & Johnson to Acquire Taris Biomedical

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

As a new decade has begun, this editorial reviews some of the biggest, brightest, and boldest happenings from the industry over the past 10 years.

Pharma’s Decade in Brief

The divestment of the pharma and food ingredients business is in line with Ferrer’s new strategy to focus on the core business of branded pharmaceuticals.

Riverside Acquires Pharma and Food Ingredients Biz from Ferrer

The acquisition expands Charles River’s scientific capabilities in cell therapy development.

Charles River Laboratories to Acquire HemaCare in $380-Million Deal

The deal was approved by the Federal Trade Commission following a 10-month investigation.

Roche Completes $4.3 Billion Acquisition of Spark Therapeutics After FTC Investigation

Through the acquisition, Merck will gain access to ArQule’s lead investigational candidate, ARQ 531, a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently in a Phase II dose expansion study for the treatment of B-cell malignancies.

Mergers and Acquisitions